Novan leans on its spinout, Know Bio, to bolster acne drug pipeline
Morrisville-based Novan (Nasdaq: NOVN) is broadening its focus through acquiring new intellectual property rights and is closing in on a deal to move its acne product forward.
Through a deal with Know Bio – which was spun out from Novan prior to Novan’s IPO last year – Novan has acquired the exclusive worldwide rights to applications of nitric-oxide-based products for the treatment of cancer-causing viruses. Those viruses include human papillomavirus (HPV)-associa ted sexually transmitted infections.
Novan…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jennifer Henderson Source Type: news
More News: Acne | Biotechnology | Cancer | Cancer & Oncology | Genital Warts | Health Management | Human Papillomavirus (HPV) | STDs